166 patents
Page 7 of 9
Utility
Heterodimeric antibodies that bind CD3 and tumor antigens
12 Jan 21
The present invention is directed to novel heterodimeric antibodies.
Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
Filed: 25 Nov 15
Utility
Heterodimeric proteins
7 Dec 20
In one aspect, the present invention provides heterodimeric antibodies comprising a first monomer comprising a first heavy chain constant domain comprising a first variant Fc domain and a first antigen binding domain and a second monomer comprising a second heavy chain constant domain comprising a second variant Fc domain and a second antigen binding domain.
Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
Filed: 16 Mar 14
Utility
Bispecific antibodies that bind to CD38 and CD3
7 Dec 20
The invention provides novel heterodimeric proteins including heterodimeric antibodies.
Matthew J. Bernett, Seung Y. Chu, Gregory Moore, John Desjarlais
Filed: 16 Oct 17
Utility
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
30 Nov 20
The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.
Matthew J. Bernett, Gregory L. Moore, John Desjarlais, Rumana Rashid
Filed: 9 Oct 12
Utility
Modulation of T Cells with Bispecific Antibodies and FC Fusions
28 Oct 20
The present invention relates to methods and compositions for modulating T cells.
Seung Chu, Matthew Bernett, Dilki Wickramarachichi, John Desjarlais
Filed: 18 Dec 19
Utility
NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS
21 Oct 20
The present invention relates to immunoglobulins that bind IgE and FcγRIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE.
John R. Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
Filed: 4 Feb 20
Utility
Optimized Antibodies That Target CD19
7 Oct 20
The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcγR or alters effector function as compared to the parent antibody.
Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik Weiking Pong, John O. Richards, Eugene Alexander Zhukovsky
Filed: 31 Mar 20
Utility
Heterodimeric Antibodies That Bind ENPP3 and CD3
7 Oct 20
The present invention is directed to antibodies, including novel antigen binding domains and heterodimeric antibodies, that bind Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3).
Rumana Rashid, Umesh S. Muchhal, Gregory Moore, Alex Nisthal, Seung Chu, Sung-Hyung Lee, Yoon Kyung Kim
Filed: 27 Feb 20
Utility
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
5 Oct 20
The present invention is directed to bispecific, heterodimeric immunomodulatory antibodies.
Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon
Filed: 29 Aug 17
Utility
Bispecific checkpoint inhibitor antibodies
28 Sep 20
The present invention is directed to compositions that include programmed cell death 1 (PD-1) binding domains and antibodies that include such PD-1 binding domains.
Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon, Alex Nisthal
Filed: 13 Jun 17
Utility
Complement component C5 antibodies
24 Aug 20
The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway.
Peter C. Baciu, Yanbin Liang, Jason Guu, Matthew Bernett, Umesh Muchhal, John Desjarlais
Filed: 1 Apr 18
Utility
Fc VARIANTS WITH ALTERED BINDING TO FcRn
19 Aug 20
The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
Aaron Keith Chamberlain, Bassil Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
Filed: 26 Feb 20
Utility
Fc VARIANTS WITH ALTERED BINDING TO FcRn
12 Aug 20
The present application relates toa variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
Aaron Keith Chamberlain, Bassil Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
Filed: 11 Jun 19
Utility
Heterodimeric proteins
10 Aug 20
The invention provides novel heterodimeric proteins including heterodimeric antibodies.
John R. Desjarlais, Gregory L. Moore, Rumana Rashid, Matthew J. Bernett
Filed: 13 Jan 14
Utility
Heterodimeric proteins
10 Aug 20
The invention provides novel heterodimeric proteins including heterodimeric antibodies.
Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
Filed: 7 May 17
Utility
IL-12 Heterodimeric Fc-fusion Proteins
8 Jul 20
The present invention provides novel IL-12 Fc fusion proteins, methods of making and using the same.
Matthew Bernett, John R. Desjarlais, Rajat Varma, Ke Liu, Nargess Hassanzadeh-Kiabi, Rumana Rashid
Filed: 2 Oct 19
Utility
Heterodimeric Antibodies That Bind CD3 and Psma
8 Jul 20
The present invention is directed to heterodimeric antibodies that bind CD3 and PSMA.
Gregory Moore, John Desjarlais, Seung Chu
Filed: 6 Dec 16
Utility
Heterodimeric Antibodies That Bind CD3 and CD38
24 Jun 20
The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.
Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Y. Chu, Rumana Rashid, Umesh Muchhal
Filed: 21 Oct 19
Utility
Methods of Treating Neurological Diseases
3 Jun 20
The present disclosure is directed to a method of treating neurological disorder comprising measuring c-reactive protein in a patient and peripherally administering to the patient a DN-TNF polypeptide that inhibits the activity of soluble TNF-but not transmembrane TNF-α.
David Szymkowski, Malu Tansey, Lesley Probert
Filed: 31 Mar 19
Utility
Heterodimeric Antibodies That Bind Fibroblast Activation Protein
27 May 20
The present invention relates to novel antigen binding domains and heterodimeric antibodies that bind Fibroblast Activation Protein (FAP).
John Desjarlais, Alex Nisthal, Seung Chu
Filed: 3 Apr 19